Home Our Team Faculty Alix E. Seif, MD, MPH Profile

Alix E. Seif, MD, MPH

Alix E. Seif, MD, MPH

Attending Physician

Assistant professor, University of Pennsylvania School of Medicine

Contact Alix E. Seif, MD, MPH

Resume

    • Primary Address:
      Division of Oncology
      Children's Hospital of Philadelphia
      3501 Civic Center Blvd, CTRB 3004
      Philadelphia, PA 19104
    • 215-590-9996

      Appointments

      • Assistant Professor of Pediatrics at the Children's Hospital of Philadelphia (2011 – present)

      Education

      • MD, Oregon Health Sciences University (2002)
      • MPH, Epidemiology and Biostatistics, Oregon Health Sciences University (2002)
      • MA, Linguistics, McGill University (1995)
      • BA, Linguistics - Honours, First Class, McGill University (1992)

      Expertise:

        Hematologic malignancies
        Blood and marrow transplantation

      Extended Bio

      Despite advances in treating pediatric acute lymphoblastic leukemia (ALL), children with relapsed disease have dismal outcomes and are often not curable with chemotherapy alone. Furthermore, children with residual leukemia cells after chemotherapy are highly likely to relapse. Simply adding more traditional chemotherapy will not treat chemotherapy-resistant cells and just adds toxicity; we are developing other approaches to eliminating chemoresistant ALL with the goal of improving efficacy and reducing toxicity.

      We have shown that a drug that stimulates the immune system like a virus or bacteria does can cure ALL in mice, results leading to a national phase I/II pediatric clinical trial. This type of immune stimulation generates long-term immune memory like a vaccine does, allowing the immune system to recognize and kill residual leukemia cells long after the leukemia is in remission. Our current focus takes a novel two-pronged approach to enhance the immune system’s ability to kill ALL, combining our immune stimulant with drugs already in clinical use that make tumor cells more recognizable to the immune system. In addition, we have identified the largest group of pediatric ALL patients ever reported and will use this cohort to evaluate our findings in children with ALL who have had immune stimulation by infections.

      Immune stimulation may help children with chemotherapy-resistant ALL and may improve efficacy of current therapies without adding new toxicity. Furthermore, if we stimulate a child’s immune system to recognize ALL, long-term memory effects may prevent relapse for his or her lifespan. We have compelling laboratory data that immune stimulation is effective; however, most treatments that work in the lab fail in clinical trials. Using existing data from a nationwide group of children with ALL, we can evaluate immune stimulation in children long before Phase III testing. This approach will also apply to other rare pediatric cancers, such as acute myeloid leukemia (AML).

      Publications

      • Fisher BT, Sammons JS, Li Y, de Blank P, Seif AE, Huang Y-S, Kavcic M, Klieger S, Harris T, Torp K, Rheam D, Shah A, Aplenc R.. Variation in Risk of Hospital-onset Clostridium difficile Infection across Beta-lactam Antibiotics in Children with New-Onset Acute Lymphoblastic Leukemia. Journal of the Pediatric Infectious Diseases Society. 2013.
      • Maude SL*, Fitzgerald J*, Fisher BT. Li Y, Huang YS, Torp K, Seif AE, Kavcic M, Walker DM, Leckerman KH, Kilbaugh TJ, Rheingold SR, Sung L, Zaoutis TE, Berg RA, Nadkarni VM, Thomas NJ, Aplenc R.. Outcome of pediatric acute myeloid leukemia patients receiving intensive care in the United States. Pediatric Critical Care Medicine. 2013.
      • Fisher BT, Harris T, Torp K, Seif AE, Shah A, Huang Y-SV, Bailey LC, Kersun LS, Reilly AF, Rheingold SR, Walker D, Li Y, Aplenc R. Establishment of an 11-Year Cohort of 8733 Pediatric Patients Hospitalized at United States Free-standing Children?s Hospitals with de novo Acute Lymphoblastic Leukemia from Healthcare Administrative Data. Medical Care. Vol epub. 2012 March.
      • Fisher BT, Kavcic M, Li Y, Seif AE, Bagatell R, Huang YV, Zaoutis T, Torp K, Leckerman K, Aplenc R. Antifungal prophylaxis associated with decreased induction mortality rates and resource utilized in children with new onset acute myeloid leukemia. Clinical Infectious Disease. 2013.
      • Seif AE, Fisher BT, Li Y, Torp K, Rheam DP, Huang YSV, Harris T, Shah A, Hall M, Fieldston ES, Kavcic M, Vujkovic M, Bailey LC, Kersun LS, Reilly AF, Rheingold SR, Walker DM, Aplenc R.. Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia. Pediatric Blood & Cancer. 2013.
      • Fisher BT, Singh S, Huang YSV, Li Y, Gregory J, Walker D, Seif AE, Kavcic M, Aplenc R. Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009. Pediatric Blood & Cancer. 2013.
      • Lothstein K, Fisher BT, Li Y, Seif A, Harris T, Torp K, Kavcic M, Huang YSV, Rheingold SR, Aplenc R.. Zoonotic Infections in Pediatric Patients with Acute Leukemia. Pediatric Blood & Cancer. 2013.
      • Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, Fitzgerald JC, Aplenc R, Gore L, and Grupp SA. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine directed therapy. Blood. Vol 121(26) . 2013:5154-7.
      • Fisher BT, Gerber JS, Leckerman K, Seif AE, Huang YS, Li Y, Harris T, Torp K, Rheam D, Shah A, Walker D, Aplenc R.. Variation in Hospital Antibiotic Prescribing Practices for Children with Acute Lymphoblastic Leukemia. Leukemia and Lymphoma. Vol 54(8) . 2013:1633-9.